STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more

GSK acquired Nuvalent, a cancer drug developer, in a $10.6 billion deal to expand its oncology portfolio, while Merck and Gilead Sciences reported success in final-stage trials for a once-weekly HIV pill combining their experimental drugs. The GSK acquisition highlights ongoing biopharma industry consolidation as companies bolster pipelines amid generic competition.